MedTech sales teams that use Artificial Intelligence are three times more likely to hit their quotas, according to a recent survey. Salesforce’s 2026 State of Sales report found that sales teams using AI tools are 3.7 times more likely to meet their targets. This data makes a strong case for adoption, yet the reality is more complicated. The MedTech survey found that only 36% of respondents use AI regularly, with most of those users deploying the technology for administrative tasks like drafting emails or summarizing meetings. Just 11% of surveyed teams use AI to uncover insights that they would not have found otherwise, such as researching new opportunities.
Where the Value Lies
While administrative work remains a burden, with many reps spending hours documenting activities or updating CRM systems, AI has proven capable of significant time savings. AI users reported saving between four and six hours per week on these tasks, with more than a quarter saving more than six hours. When asked what they would do with five to ten additional hours, 62% said they would spend the time preparing for calls and meetings, and 46% said they would spend it meeting with customers and prospects. This suggests that reps are looking to reclaim time for the activities that directly influence sales outcomes, rather than simply completing paperwork more quickly.
The biggest challenge for the industry is not the availability of technology, but turning fragmented information into actionable insight. Sales teams need detailed, data-driven guidance on where to go next, the fastest route to get there, and what to say when they arrive. The survey shows that 84% of reps lose three to 10 hours a week to nonproductive tasks. Respondents identified key barriers to quota attainment, including issues with account prioritization, a lack of market insights, and the challenge of proving value to buyers. When asked what would improve pipeline growth, discovering new providers and identifying new opportunities rose to the top.
For a MedTech sales rep, the ability to immediately identify an account with declining procedure volume that threatens quota attainment, uncover a high-potential physician who has not been visited in months, or spot a nearby opportunity showing signs of competitive encroachment could make a significant difference. While one approach helps a rep complete tasks more quickly, the other helps a rep determine which opportunities deserve attention.
Read Also: Agentic AI Drives Major Shift in Healthcare Adoption
The organizations that gain the greatest advantage may be the ones that move beyond productivity and toward real commercial intelligence. Ultimately, the challenge lies in deciding what deserves attention in the first place, and AI’s greatest value lies in removing tasks that distract from relationship-building, allowing reps to focus on the work that matters most.
The Productivity Trap
This time loss directly impacts their ability to reach sales targets. Proving value to buyers also presents a major hurdle. These factors indicate that the primary struggle is not completing tasks, but deciding which tasks deserve attention.
Complexity Demands New Approaches
MedTech commercialization is becoming increasingly difficult. Purchasing decisions now involve a wider network of people, including administrators, Value Analysis Committees, supply chain leaders, and finance teams. Hospital consolidation has concentrated purchasing power, making the financial case for a technology nearly as important as the clinical one. While physicians remain critical stakeholders, the survey highlights the need for sales teams to understand where AI creates the greatest value and to provide ways to unlock that value, particularly in strategic areas such as identifying opportunities and prioritizing accounts.
